HRSA proposed rule would establish dispute resolution process for 340B program
The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs purchased through the program. Under the proposed process, which also would be available to drug manufacturers, a decision-making body within the Department of Health and Human Services would review and resolve the claims. The proposed rule will be published in the Aug. 12 Federal Register with comments accepted through Oct. 11. AHA staff are reviewing the rule, and member hospitals that are 340B participants will receive more information.
Related News Articles
Headline
A new report from KFF reveals that Medicare Advantage enrollees had access to just 48% of the physicians available to Traditional Medicare beneficiaries in…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…
Headline
Medicare open enrollment for 2026 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…